Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06191796
Title Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Exelixis
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Exelixis Site #8 Los Angeles California 90033 United States Details
Exelixis Site #9 Miami Florida 33176 United States Details
Exelixis Clinical Site #1 Orlando Florida 32804 United States Details
Exelixis Site #11 Tampa Florida 33612 United States Details
Exelixis Site #6 Scarborough Maine 04074 United States Details
Exelixis Site #5 Saint Louis Missouri 63110 United States Details
Exelixis Site #15 Bronx New York 10469 United States Details
Exelixis Clinical Site #3 New Hyde Park New York 11776 United States Details
Exelixis Site #14 New York New York 10028 United States Details
Exelixis Site #13 Shirley New York 11987 United States Details
Exelixis Clinical Site #2 Nashville Tennessee 37203 United States Details
Exelixis Clinical Site #16 Salt Lake City Utah 84112 United States Details
Exelixis Site #4 Spokane Washington 99208 United States Details
Exelixis Site #12 Madison Wisconsin 53792 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field